VRTX - Vertex Pharmaceuticals Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
159.19
+2.62 (+1.67%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close156.57
Open157.09
Bid150.00 x 1100
Ask160.00 x 800
Day's Range155.76 - 160.28
52 Week Range125.50 - 178.15
Volume1,658,668
Avg. Volume1,551,564
Market Cap40.566B
Beta1.92
PE Ratio (TTM)180.08
EPS (TTM)0.88
Earnings DateJul 24, 2018 - Jul 30, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est191.45
Trade prices are not sourced from all markets
  • Business Wire2 days ago

    Vertex’s Paul Negulescu Awarded the Warren Alpert Foundation Prize for Pioneering Discoveries in Cystic Fibrosis

    Vertex Pharmaceuticals Incorporated today announced that Senior Vice President Paul Negulescu has been named one of the winners of this year’s Warren Alpert Foundation Prize for “transformative discoveries in the fields of genetics, physiology, pulmonology and pharmacology that led to the development of life-altering precision-targeted treatments for the devastating multi-organ disease cystic fibrosis ...

  • Investopedia2 days ago

    3 Big Biotechs That Can Beat the Market

    Trading well below their one-year highs, big biotech stocks look set for a rebound as their fundamentals are showing signs of improvement. More stable product pricing environments, earnings improvement and successful new drug trials, are just a few of the factors that could lead to a biotech rally in the second half of the year, with firms like Gilead Sciences Inc. ( GILD), Alexion Pharmaceuticals Inc. ( ALXN) and Vertex Pharmaceuticals Inc. ( VRTX) leading the charge.

  • Solid Biosciences’ Stock Price Rose 46.6% on June 19
    Market Realist3 days ago

    Solid Biosciences’ Stock Price Rose 46.6% on June 19

    On June 19, Solid Biosciences’ (SLDB) stock price rose ~46.6% to $43.00. On June 19, Solid Biosciences’ stock price hit a 52-week high of $54.84.

  • 2 High-Flying Biotech Stocks With Even More Room to Grow
    Motley Fool3 days ago

    2 High-Flying Biotech Stocks With Even More Room to Grow

    These two red-hot biotechs are showing no signs of slowing down.

  • CRISPR, Intellia, and Caribou Receive a US Genome-Editing Patent
    Market Realist4 days ago

    CRISPR, Intellia, and Caribou Receive a US Genome-Editing Patent

    CRISPR, Intellia, and Caribou Receive a US Genome-Editing PatentCRISPR-Cas9 genome editing granted US patent

  • Business Wire5 days ago

    Vertex Opens Expanded Research Site in San Diego

    Vertex Pharmaceuticals Incorporated (VRTX) today announced the opening of its new 170,000 square foot research facility in Torrey Pines, San Diego. The San Diego site is one of Vertex’s three global research hubs, and is where the Company’s three breakthrough cystic fibrosis (CF) medicines were discovered. “Our researchers in San Diego have spent the last 20 years doing what was once thought impossible – developing the first medicines that treat the underlying cause of cystic fibrosis,” said Dr. David Altshuler, Executive Vice President, Global Research and Chief Scientific Officer.

  • Business Wire5 days ago

    Vertex Announces Long-Term Access Agreement in Sweden for Cystic Fibrosis Medicine ORKAMBI® (lumacaftor/ivacaftor)

    Vertex Pharmaceuticals Incorporated (VRTX) today announced that ORKAMBI® (lumacaftor/ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis (CF) in people with two copies of the F508del mutation, ages six and older, will be reimbursed in Sweden after concluding the three-party negotiations with TLV and the county councils. “We are delighted that people with CF in Sweden will join the thousands of others around the world who are already benefitting from our CF medicines,” said Simon Bedson, International General Manager at Vertex.

  • Barrons.com8 days ago

    Big Biotech Set for Earnings Blowout?

    Earlier this year, Oppenheimer's Hartaj Singh argued that earnings expectations were too high for big biotech companies heading into the first-quarter reporting season. Ahead of the reports, due out in mid-July, Singh argues that fundamentals for large-cap biotech, as well as sector sentiment are "slowly but surely improving," leading him to believe that the stocks could outperform, led by Gilead Sciences (GILD), Alexion Pharmaceuticals (ALXN), and Vertex Pharmaceuticals (VRTX). For Gilead, he's upbeat about a more stable pricing environment for hepatitis C treatments, while investors are getting more interested in the company's "budding" immunology and nonalcoholic steatohepatitis (NASH) franchises, setting up an attractive risk-reward profile going into the second quarter.  Alexion reported "stellar" first-quarter earnings, and Singh sees another strong quarter ahead, and he wonders "when the Street will start giving management credit for relentless execution." Vertex is one of his favorite large-cap biotechs, and he sees a good report ahead, along with an update about the progress of its cystic-fibrosis drugs.

  • Business Wire9 days ago

    The Vertex Foundation and Employees Donate $1 Million Through Matching Gift Program

    Vertex Pharmaceuticals Incorporated (VRTX) today announced that Vertex employees and The Vertex Foundation have together donated over $1 million through the Company’s new dollar-for-dollar matching gift program. The funds demonstrate the Company’s long-term commitment to giving back and to supporting employees’ deep commitment to strengthening their communities. The matching gift program launched on November 28, 2017 and was created to extend the impact of employee donations to qualified nonprofit organizations.

  • Bloomberg11 days ago

    The Quant King, the Drug Hunter, and the Quest to Unlock New Cures

    Ten years ago, drug hunter Mark Murcko was thinking about motion. Then the chief technology officer of Vertex Pharmaceuticals Inc., Murcko was a pioneer. Unraveling how diseased proteins are constructed made Vertex, founded in 1989, into one of the largest biotechnology companies in the world.

  • 2 Cheap Growth Stocks to Buy Right Now
    Motley Fool12 days ago

    2 Cheap Growth Stocks to Buy Right Now

    Crispr Therapeutics and Viking Therapeutics are both grossly undervalued relative to their long-term prospects right now.

  • Now's the Time to Buy These 3 Stocks
    Motley Fool15 days ago

    Now's the Time to Buy These 3 Stocks

    There's no need to wait with these three hot stocks.

  • Vertex Gets Some Breathing Room As Rival Disappoints In Cystic Fibrosis
    Investor's Business Daily16 days ago

    Vertex Gets Some Breathing Room As Rival Disappoints In Cystic Fibrosis

    Vertex is getting some breathing room, an analyst said Thursday, as rival Proteostasis tumbled on disappointing results from a study of its cystic fibrosis drug.

  • Business Wire16 days ago

    Vertex Data Presented at European Cystic Fibrosis Society (ECFS) Conference Demonstrate Early and Long-Term Disease-Modifying Potential of Treating the Underlying Cause of CF

    Vertex Pharmaceuticals Incorporated (VRTX) today announced 10 scientific abstracts from the company’s portfolio of cystic fibrosis (CF) medicines are being presented at the 41st European Cystic Fibrosis Conference taking place June 6-9, 2018, in Belgrade, Serbia. Collectively, the data support the potential disease-modifying benefits of treating the underlying cause of CF and Vertex’s progress toward enhancing and expanding treatment options for all people living with CF. Data from the ongoing Phase 3, open-label ARRIVAL study presented at an oral session and published online today in The Lancet Respiratory Medicine show that treatment with KALYDECO® (ivacaftor) resulted in substantial decreases in mean sweat chloride as well as improvements to multiple efficacy endpoints, suggesting the potential to preserve pancreatic function and modify the course of CF beginning in children as young as one year of age.

  • Business Wire17 days ago

    Vertex to Present at the Goldman Sachs Healthcare Conference on June 13

    Vertex Pharmaceuticals Incorporated (VRTX) today announced that management will present at the Goldman Sachs Healthcare Conference on Wednesday, June 13, 2018 at 5:40 p.m. ET (2:40 p.m. PT). The audio portion of management’s remarks will be available live through Vertex’s website, www.vrtx.com in the “Investors” section under the “News and Events” page. A replay of the conference webcast will be archived on the company’s website.

  • Biotech Stock Roundup: Regeneron, Celgene, Amgen Impress at ASCO
    Zacks17 days ago

    Biotech Stock Roundup: Regeneron, Celgene, Amgen Impress at ASCO

    The biotech sector was in focus last week due to the ASCO meet at Chicago where biotech bigwigs presented data on their oncology drugs and promising pipeline candidates.

  • Interested In Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)? Here’s What Its Recent Performance Looks Like
    Simply Wall St.18 days ago

    Interested In Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)? Here’s What Its Recent Performance Looks Like

    When Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced its most recent earnings (31 March 2018), I did two things: looked at its past earnings track record, then look at what is happeningRead More...

  • ACCESSWIRE18 days ago

    Free Technical Research on Versartis and Three More Biotech Equities

    LONDON, UK / ACCESSWIRE / June 5, 2018 / If you want a free Stock Review on VSAR sign up now at www.wallstequities.com/registration. This Tuesday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: Versartis Inc. (NASDAQ: VSAR), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), 22nd Century Group Inc. (NYSE AMER: XXII), and Abeona Therapeutics Inc. (NASDAQ: ABEO).

  • Buy These 2 Biotech Stocks on the Dip After an FDA Delay
    Motley Fool18 days ago

    Buy These 2 Biotech Stocks on the Dip After an FDA Delay

    Don't worry about the FDA's clinical hold on gene-editing therapy CTX001. Vertex and CRISPR Therapeutics stocks will bounce back.

  • After Soaring to New Highs, Crispr Therapeutics AG Stock Ripe for a Fall
    InvestorPlace18 days ago

    After Soaring to New Highs, Crispr Therapeutics AG Stock Ripe for a Fall

    Quite often in stock markets, companies that offer something novel and unique attract speculators. CRSP stock has two positive catalysts at this time. Fundamentally, the company’s high valuation could limit any more near-term upside, though.

  • Zacks Investment Ideas feature highlights: CRISPR, Intellia Therapeutics, Editas and Vertex
    Zacks22 days ago

    Zacks Investment Ideas feature highlights: CRISPR, Intellia Therapeutics, Editas and Vertex

    Zacks Investment Ideas feature highlights: CRISPR, Intellia Therapeutics, Editas and Vertex

  • Should You Buy the Dip in CRISPR Therapeutics?
    Zacks23 days ago

    Should You Buy the Dip in CRISPR Therapeutics?

    Should You Buy the Dip in CRISPR Therapeutics?

  • Benzinga23 days ago

    3 Possible Outcomes From The Clinical Hold On Crispr Therapeutics's Sickle Cell Candidate

    The FDA placed a clinical hold on the Investigational New Drug application for Crispr's CTX001 for the treatment of sickle cell disease, Crispr and its partner Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) said in a press release. The details of the FDA's hold are not revealed to the market, so the overall implications for Crispr aren't fully known, Chardan's Gbola Amusa said in a research report. Crispr and Vertex expect to receive additional information on the FDA's list of questions in the "near future" and will "work rapidly" with the FDA toward a solution, the press release said.

  • Peaking late: How Vertex became biotech's model citizen
    American City Business Journals23 days ago

    Peaking late: How Vertex became biotech's model citizen

    The story of how Vertex went from being a potential also-ran to a local giant with $2 billion in annual revenue and 2,300 employees offers some lessons on how to stand out in this increasingly crowded and competitive sector.

  • Vertex/CRISPR's Sickle Disease Candidate Put on Hold by FDA
    Zacks23 days ago

    Vertex/CRISPR's Sickle Disease Candidate Put on Hold by FDA

    FDA places clinical hold on a Vertex (VRTX) and CRISPR Therapeutics' IND application for CTX001 for the treatment of sickle cell disease.